What is the role of SBRT in polymetastatic lung cancer?

References

1. [1]

   Wang W, Ye L, Chen Y et al.. “Enhanced efficacy of lung cancer treatment with radiotherapy and immune checkpoint inhibitors without increased pneumonia risk: a systematic review and meta-analysis of randomized controlled trials.” Frontiers in immunology (2025). PMID: 41438748 ↗

   L1SR_MA_RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, On the Horizon
2. [2]

   Pennathur A, Lanuti M, Merritt RE et al.. “Treatment of High-Risk Patients with Stage I Non-Small Cell Lung Cancer.” Seminars in thoracic and cardiovascular surgery (2024). PMID: 39672521 ↗

   L1GUIDELINECited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
3. [3]

   Adar S, Ádám A, Balogh T et al.. “Sublobar resection, stereotactic body radiotherapy, and thermal ablation for early-stage non-small cell lung cancer: a systematic review and meta-analysis.” Lung cancer (Amsterdam, Netherlands) (2026). PMID: 42202379 ↗

   L1SR_OBSCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
4. [4]

   Yang X, Xing Z, Long S et al.. “Comparative effectiveness for early-stage NSCLC without lymph node involvement based on prospective studies.” International journal of surgery (London, England) (2025). PMID: 40434735 ↗

   L2SR_OBSCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
5. [5]

   Gooijer SA, Gazendam ASM, Torensma B et al.. “Metastasectomy versus stereotactic body radiotherapy for patients with oligometastatic colorectal lung metastases: a systematic review.” European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology (2025). PMID: 40300380 ↗

   L2SR_OBSCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
6. [6]

   Wu GJ, Zhang Y, Liang R et al.. “Comparison of Survival Outcomes of Early-Stage Non-Small-Cell Lung Cancer in Elderly Patients (≥ 70 years) Treated With Stereotactic Body Radiotherapy Versus Surgical Resection.” World journal of surgery (2025). PMID: 40214658 ↗

   L2SR_OBSCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
7. [7]

   Pennathur A, Lanuti M, Merritt RE et al.. “Systematic Review of the Comparative Studies of Image-Guided Thermal Ablation, Stereotactic Radiosurgery, and Sublobar Resection for Treatment of High-Risk Patients with Stage I Non-Small Cell Lung Cancer.” Seminars in thoracic and cardiovascular surgery (2024). PMID: 39675493 ↗

   L2SR_OBSCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
8. [8]

   Wolf A, Loo BW, Mak RH et al.. “Systematic Review of Stereotactic Ablative Radiotherapy (SABR)/Stereotactic Body Radiation Therapy (SBRT) for Treatment of High-Risk Patients with Stage I Non-Small Cell Lung Cancer.” Seminars in thoracic and cardiovascular surgery (2024). PMID: 39674443 ↗

   L2SR_OBSCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
9. [9]

   Cho BC, Lim SM, Lee SH et al.. “MORPHEUS-Lung: biomarkers and clinical response to atezolizumab + bevacizumab + stereotactic body radiotherapy in patients with metastatic non-small cell lung cancer.” Lung cancer (Amsterdam, Netherlands) (2026). PMID: 42103553 ↗

   L1RCTCited in: Bottom Line, Current Evidence and Standard
10. [10]

    Wang Y, Donovan EK, Levine MN et al.. “Stereotactic Versus Conventional Radiotherapy in Medically Inoperable Stage I Non-Small Cell Lung Cancer: A Bayesian Reanalysis of the LUSTRE Randomized Trial.” Clinical lung cancer (2026). PMID: 41997828 ↗

    L1RCTCited in: Bottom Line, Current Evidence and Standard
11. [11]

    Kothari G, O'Byrne KJ, Brown C et al.. “A Randomized Phase 2 Trial of Nivolumab and Stereotactic Ablative Body Radiation Therapy in Advanced Non-Small Cell Lung Cancer, Progressing After First- or Second-Line Chemotherapy (NIVORAD).” International journal of radiation oncology, biology, physics (2025). PMID: 41422917 ↗

    L1RCTCited in: Current Evidence and Standard, On the Horizon
12. [12]

    Hou Q, Parpia S, Wierzbicki M et al.. “Quality of Life of Stereotactic Versus Hypofractionated Radiation Therapy for Inoperable Stage I Non-Small Cell Lung Cancer: Results From the LUSTRE Trial.” International journal of radiation oncology, biology, physics (2025). PMID: 41275977 ↗

    L1RCTCited in: Current Evidence and Standard, On the Horizon
13. [13]

    Simone CB, Bogart JA, Cabrera AR et al.. “Radiation Therapy for Small Cell Lung Cancer: An ASTRO Clinical Practice Guideline.” Practical radiation oncology (2020). PMID: 32222430 ↗

    L1GUIDELINECited in: Applicability and Caveats
14. [14]

    Li Q, Ma H, Zheng R et al.. “Durvalumab Combined With Chemotherapy and SABR Therapy in Patients With Oligometastatic Non-small Cell Lung Cancer: A Multicenter Phase 2 Study.” International journal of radiation oncology, biology, physics (2025). PMID: 41005623 ↗

    L4TRIAL_NONRANDOMCited in: Applicability and Caveats, On the Horizon
15. [15]

    Lieverse RIY, Van Limbergen EJ, Oberije CJG et al.. “Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial.” BMC cancer (2020). PMID: 32539805 ↗

    L5TRIAL_NONRANDOMCited in: Applicability and Caveats
16. [16]

    Kuncman Ł, Fijuth J, Tworek D et al.. “Radiotherapy(R) Integration(I) Strategy for Small(S)-Cell Lung Cancer in Extensive(E) Stage (RISE) with up to 10 metastases- a study protocol of a randomized phase II trial.” BMC cancer (2025). PMID: 39856583 ↗

    L5TRIAL_NONRANDOMCited in: Applicability and Caveats
17. [17]

    Wu Y, Li H, Peng Y et al.. “Sustained complete response to TMEp-CI-M platform in refractory small-cell lung cancer with brainstem metastasis: a case report with over 20 months of disease-free survival.” Frontiers in immunology (2026). PMID: 42305556 ↗

    L4CASE_REPORTCited in: Applicability and Caveats
18. [18]

    Wang X, Lu Z, Zeng Z et al.. “Thoracic stereotactic body radiation therapy plus first-line tyrosine kinase inhibitors for patients with epidermal growth factor receptor-mutant polymetastatic non-small-cell lung cancer: A propensity-matched retrospective study.” Medicine (2021). PMID: 34664886 ↗

    L3COHORTCited in: Applicability and Caveats
19. [19]

    Nicosia L, Figlia V, Ricottone N et al.. “Stereotactic body radiotherapy (SBRT) and concomitant systemic therapy in oligoprogressive breast cancer patients.” Clinical & experimental metastasis (2022). PMID: 35511313 ↗

    L3OTHERCited in: Applicability and Caveats
20. [20]

    Videtic GMM, Donington J, Giuliani M et al.. “Stereotactic body radiation therapy for early-stage non-small cell lung cancer: Executive Summary of an ASTRO Evidence-Based Guideline.” Practical radiation oncology (2017). PMID: 28596092 ↗

    L1OTHERCited in: Applicability and Caveats
21. [21]

    Cravereau O, Bourbonne V, Vaugier L et al.. “AFSOS-SFRO Guidelines on Radiation-Induced Lung Injury.” Clinical lung cancer (2025). PMID: 40796462 ↗

    L1GUIDELINECited in: On the Horizon
22. [22]

    Cammareri E, Duijm M, Granton PV et al.. “High-Dose REirradiation for In-Field Recurrent Lung Cancer in the THOrax (RETHO): Outcomes of a Phase 2 Prospective Clinical Trial.” International journal of radiation oncology, biology, physics (2025). PMID: 41429403 ↗

    L4TRIAL_NONRANDOMCited in: On the Horizon
23. [23]

    Zhang R, Chen M, Yin N et al.. “Low-dose radiation and stereotactic body radiotherapy with PD-1 inhibitor sintilimab and chemotherapy for first-line treatment of locally advanced or metastatic squamous lung cancer: protocol for a randomised phase II trial (IHC002 study).” BMJ open (2025). PMID: 40887121 ↗

    L5TRIAL_NONRANDOMCited in: On the Horizon
24. [24]

    Levy A, Tonneau M, Darréon J et al.. “Radiotherapy for lung metastases.” Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique (2025). PMID: 41223825 ↗

    L1GUIDELINECited in: On the Horizon